SCHEMBL2895816

SCHEMBL2895816

CNc1c(C(=O)O)sc2cccnc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIMK1 P53667 3/20 0.50
KDM4E B2RXH2 5/20 0.40
KMT2A Q03164 2/20 0.40
MCL1 Q07820 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
LMNA P02545 3/20 0.36
TDP1 Q9NUW8 2/20 0.36
POLB P06746 1/20 0.36
ALDH1A1 P00352 3/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
MAPK1 P28482 1/20 0.36
KDM6B O15054 1/20 0.36
KDM6A O15550 1/20 0.36
TET3 O43151 1/20 0.36
KDM4A O75164 1/20 0.36
KDM4B O94953 1/20 0.36
KDM5C P41229 1/20 0.36
KDM4D Q6B0I6 1/20 0.36
TET2 Q6N021 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8142918 0.85 LIMK1 (0.48) LIMK1KDM4EKMT2ALMNATDP1
SCHEMBL27404716 0.78 LIMK1 (0.55) LIMK1KDM4EKMT2AMCL1LMNA
SCHEMBL10507045 0.78 LIMK1 (0.55) LIMK1KDM4EKMT2AMCL1LMNA
SCHEMBL8507168 0.76 LIMK1 (0.77) LIMK1KDM4EKMT2AMCL1LMNA
SCHEMBL1098450 0.76 LIMK1 (0.54) LIMK1KDM4EKMT2AMCL1LMNA
SCHEMBL4859707 0.76 LIMK1 (0.50) LIMK1KDM4EKMT2AMCL1NPC1
SCHEMBL2896096 0.76 KDM4E (0.52) LIMK1KDM4EKMT2ALMNATDP1
SCHEMBL6984157 0.73 LIMK1 (0.50) LIMK1KDM4EKMT2AMCL1LMNA
SCHEMBL29631384 0.72 LIMK1 (0.49) LIMK1KDM4EKMT2AMCL1NPC1
SCHEMBL4125992 0.71 PTPN1 (0.56) LIMK1KDM4EKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7732477-B2 N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-08 US disclosed